2026-07-22T20:10:41Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/90052025-05-08T18:22:50Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608col_20.500.12105_19609

00925njm 22002777a 4500 dc Jimenez-Jorge, Silvia author Pozo Sanchez, Francisco author Mateo-Ontañon, Salvador de author Delgado-Sanz, Concepcion author Casas Flecha, Inmaculada author Garcia-Cenoz, Manuel author Castilla Catalán, Jesús author Sancho, R author Etxebarriarteun-Aranzabal, L author Quinones, C author Martinez, E author Vega, T author Garcia, A author Gimenez, J author Vanrell, Juana María author Castrillejo, D author Larrauri, Amparo author 2014-03-06 Adjusted early estimates of the 2013/14 influenza vaccine effectiveness (VE) in Spain for all age groups was 35% (95% CI: -9 to 62), 33% (95% CI: -33 to 67) and 28% (95% CI: -33 to 61) against any influenza virus type, A(H1N1)pdm09 and A(H3N2) viruses, respectively. For the population targeted for vaccination, the adjusted VE was 44% (95% CI: -11 to 72), 36% (95% CI: -64 to 75) and 42% (95% CI: -29 to 74), respectively. These preliminary results in Spain suggest a suboptimal protective effect of the vaccine against circulating influenza viruses. Euro Surveill. 2014 Mar 6;19(9). pii: 20727. 10.2807/1560-7917.es2014.19.9.20727 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 24626206 http://hdl.handle.net/20.500.12105/9005 Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study